SCHEMBL19173263

SCHEMBL19173263

NCCOc1ccc(C23CC4CC(CC2C4)C3)cc1

nearest known ligand 0.68

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.68
KMT2A Q03164 2/20 0.68
ALDH1A1 P00352 2/20 0.68
LMNA P02545 1/20 0.68
L3MBTL1 Q9Y468 1/20 0.68
ALOX5AP P20292 2/20 0.48
TAAR1 Q96RJ0 1/20 0.44
LTA4H P09960 2/20 0.44
PLA2G2A P14555 1/20 0.44
RAB9A P51151 1/20 0.43
CTSD P07339 2/20 0.39
BACE1 P56817 2/20 0.39
BACE2 Q9Y5Z0 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
ESR1 P03372 1/20 0.38
CHRNA7 P36544 1/20 0.37
CNR2 P34972 1/20 0.35
HIF1A Q16665 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19173239 0.83 MEN1 (0.97) MEN1KMT2AALDH1A1LMNAL3MBTL1
SCHEMBL19173838 0.76 EPHX2 (0.56) MEN1KMT2AALDH1A1RAB9A
SCHEMBL21606698 0.75 ALDH1A1 (0.51) MEN1KMT2AALDH1A1LMNAL3MBTL1
SCHEMBL19173837 0.74 SIGMAR1 (0.58) ALDH1A1LMNA
Hydrochloric Acid SCHEMBL29649691 0.71 MEN1 (0.54) MEN1KMT2AALDH1A1LMNAL3MBTL1
SCHEMBL21606691 0.70 KDM4E (0.50) MEN1KMT2AALDH1A1LMNAL3MBTL1
SCHEMBL6714503 0.70 TAAR1 (0.75) MEN1KMT2AALDH1A1LMNAL3MBTL1
SCHEMBL19362954 0.68 SRD5A2 (0.47) MEN1KMT2AHIF1A
SCHEMBL21765281 0.67 EPHX2 (0.33) MEN1KMT2AALDH1A1LMNAL3MBTL1
SCHEMBL2748297 0.66 MEN1 (0.51) MEN1KMT2AALDH1A1LMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017127306-A1 ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTION ARISAN THERAPEUTICS (US) 2017-07-27 WO disclosed